Quarterly ResultAug 6, 2026, 04:43 PM
Profound Medical Q2 Revenue Up 12.3%; Net Loss Narrows by 39.3%
AI Summary
Profound Medical Corp. reported a 12.3% increase in Q2 2026 revenue to $2.48 million, with net loss narrowing by 39.3% to $9.54 million. For the first six months of 2026, revenue surged by 61.8% to $7.82 million, and net loss decreased by 37.2% to $16.59 million. The company, a foreign private issuer, voluntarily filed this 10-Q, highlighting its TULSA-PRO system and Sonalleve platform.
Key Highlights
- Q2 2026 revenue increased 12.3% to $2.48 million from $2.21 million in Q2 2025.
- Q2 2026 net loss narrowed by 39.3% to $9.54 million, down from $15.70 million in Q2 2025.
- Basic and diluted loss per share for Q2 2026 was $0.26, an improvement from $0.52 in Q2 2025.
- Six-month revenue for 2026 grew 61.8% to $7.82 million, compared to $4.83 million in H1 2025.
- Cash balance decreased to $38.27 million as of June 30, 2026, from $59.72 million at December 31, 2025.
- Total assets decreased by 19.5% to $62.39 million from $77.48 million at year-end 2025.
- The company is in compliance with financial covenants for its CIBC Credit Agreement.
- USA revenue for Q2 2026 was $1.75 million, while Canada revenue was $0.56 million.
Price Impact
More from PROF